Pfizer entered the animal health industry in the early 1950’s. Today, Pfizer Animal Health products are sold to veterinarians, livestock producers, and horse and pet owners in more than 140 countries around the world and used in more than 30 species. Pfizer Animal Health is committed to providing high-quality, research-based health products for livestock and companion animals. The company continues to invest more in research and development than any other animal health company. This offers opportunities for substantial growth and internal synergy. Pfizer has more new animal health products in its research pipeline today than at any other time in its history. Their products include anti-inflammatory, anti-infectious, and anti-parasitic pharmaceutical medicines, vaccines and feed additives. These products are used by cattle, swine, and poultry industries, as well as, veterinarians serving both the livestock and pet markets. The animal health segment of Pfizer accounts for approximately 10% of their total revenues. ) Pfizer Animal Health revenues were $1,314 million in 1998. Some of Pfizer’s top selling animal health products are Rimadyl, Anipryl, Dectomax, and RespiSure.
The animal health segment is served in manufacturing by the 35 production plants around the world. Their products are sold through veterinarians, drug wholesalers, retail outlets, distributors, and directly to users. Animal Health gross revenues declined 1% to 1.3 billion in 1998. (Note Appendix:) This decrease is due to continuing weaknesses in the U.S. livestock market, the poor Asian economy, and the unfavorable effects of foreign exchange. This decline was offset by growth of Pfizer products; the cattle endectocide Dectomax, the canine anti-arthritic Rimadyl, and the swine vaccine RepiSure.
Pfizer is among the leading suppliers of companion animal vaccines, a $500 million market worldwide. They have over 43 animal health product candidates in clinical development. Pfizer’s Animal Health markets several feed supplements for large animals. Feed supplement product sales slowed in 1998, due in part to regulatory issues, market conditions, and competitive pressures.
Pfizer’s goal for both its business units is to meet the needs and exceed the expectations of all their customers. They achieve this with ongoing innovation through state-of-the-art research and development, ...
... middle of paper ...
...s small, medium, large, and extra large coolers to accommodate shipments ranging in size.
Government regulations are a large threat to our company. In December 1998, the Council of European Agricultural Ministers voted to ban the use of Pfizer’s antibiotic feed additive, STAFAC, throughout the European Union. It is regulations like these that can stunt our sales growth in both of our business segments. FDA requirements and reviews have increased the amount of time and money necessary to develop new products and bring them to market. Our international businesses are subject to a number of risks that are inherent in carrying on business in other countries. Some government-imposed restraints may include laws on pricing or reimbursements for use of products.
Another threat to Pfizer’s Animal Health segment is competition. Principal methods of competition in this marketplace vary depending on the particular product, but are mainly: product innovation, service, price, quality, and effective promotion to veterinary professionals and consumers. Pfizer is the leader in the animal health industry today. Some of their main competitors are Merck, Alpharma Inc, and Wingo Inc.
In the recent years the drug industry underwent a significant transformation. Many of the big companies generate high revenues, which allow them to expand. Some of them expand on their own others through mergers and the buying of smaller companies.
Although blood transfusions in the veterinary market are infrequent and the market scope is limited, Oxyglobin has the potential to become a lucrative investment for Biopure. Based on the approximate 355,000 blood transfusions (please see Exhibit 1 for the calculations behind this estimate) performed on animals in 1995, a definite opportunity exists for Oxyglobin within the veterinary blood market. Since the number of blood transfusions conducted in 1995 represented on average only 2.5% of animals suffering from acute blood loss, increased availability of animal blood could possibly stimulate the market.
Animals are tested on for many cosmetic and medical products, but the treatment of the animals and the quality of the test results are often less satisfactory than the consumer realizes. Every person has most likely purchased either a pharmaceutical or cosmetic product in his or her lives, but the careless techniques for making these products may astound individuals that rely on drugs for everyday use. According to the Food and Drug Administration, “every year about fifteen -hundred” drugs are created, but “twelve-hundred” are deemed unusable for people. Regardless of such a high number or drug rejections, about “one-million Americans are hospitalized from flaws in drugs” (“Animal Experimentation,” 2009). Most of these drugs were tested on animals before being approved for human use, which proves that animal testing is not a successful method of experimentation. Some factors should be considered when deciding what testing method is most helpful to society; whether an animal has similar genetics to humans, if testing animals are treated humanely, and the costs of conducting the tests. Scientists and animal support groups have quarreled for centuries over the morals of using testing animals and human safety when using animals for toxic experimentations. Individuals for animal testing usually claim that there are no alternatives or it is the safest out of all the methods, but he or she may not be aware of modern technologies that are capable of making a new and improved data for certain pharmaceutical products.
The history of being a veterinarian has been around since human beings have interacted with animals. For a long time, ever since man tamed animals, there is a need to monitor their health. Just as human, they suffer the same diseases: a cold, sore throat, stomach ulcer, and urolithiasis. Veterinary Medicin...
This paper is a Macroeconomic Forecast Outline of Pfizer, Inc. This outline will identify main economic indicators for Pfizer as a business entity and as a representative of pharmaceutical industry. This paper will identify sources of various data collected based on economical activity and relationships between different economical indicators.
These animals used for testing products commonly include mice, rats, rabbits, monkeys, hamsters, guinea pigs, dogs and cats. These animals are forced to test new products before they are sold to humans, and even though there are numerous valid substitutes for us to test products on, the law doesn’t require that we do. What’s even more horrifying is that no animal experiment is illegal, and therefore these ‘tests’ can be completely irrelevant to human health, and no matter how painful or cruel the test may be to animals it is completely legal. Some companies that test their products on animals include Almay, Johnson & Johnson, Clearasil, Axe, Lancôme (owned by L’Oréal), and Pantene (owned by Procter & Gamble).
Researchers who work at Merck are also stakeholders who are affected by this decision. They could possible lose jobs if Merck does employ an open innovation strategy and finds it more successful than its current innovation strategy. However, it could also develop more for them to work with and create more success. Varying ideas may be brought which works well with current ideas set in motion my Merck researchers. With the help of external ideas, they may be able to improve or create new
McTigue Pierce, L. (2005, July). Pfizer: Growth amid adversity. Food & Drug Packaging, 69, p. 60.
For commodity generic drugs, Teva has an opportunity to expand its core business into emerging markets, but there it will have to face institutional voids because such markets are driven by physicians and both physician and other people are not aware about the effectiveness of generic drugs. To cope with the challenge of institutional voids Teva have to look for some competent small pharmaceutical firms for acquisition and some big firms for the joint venture. For changing the perceptions of people and physicians, Teva will require to run marketing campaigns and direct approaches to physicians to develop a market for their products.
Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has contributed great discoveries like the first cervical cancer vaccine and great resources like the Merck Manuals which are utilized as a source of information to doctors, scientists and consumers worldwide .
There is an increasing pressure within pharmaceutical markets to reduce prices in line with medical budgets, as well as maintaining patent expirations. Being a global brand means disturbance in the operations when the market fluctuates. There is an internal weakness in the pharmaceutical industry, which includes theft and counterfeiting of drugs, and therefore is a weakness of Johnson & Johnson. While Johnson & Johnson has these specified weaknesses they deal with, there are even more opportunities which gives them an advantage for strengthening their position in the market. They already have the strength of meeting a broader range of customer needs with their products falling under three categories. Expiring patents on brand name drugs lead to an increase in the sales of generic drugs, Johnson & Johnson could capitalize upon this opportunity. With diagnostic markets growing, this positions the company in a good place as well as new medical therapies and findings that align with some of the company’s primary capabilities. Threats the company faces is with product recalls, extreme competition in pharmaceuticals that results usually in the first to enter is generally where success is determined. With technology developments, biotech concepts might possibly move the traditional pharmaceutical methods out of the
Pfizer Inc. is a large pharmaceutical company that engages in the discovery of new technologies, the manufacture of prescription and "over the counter" (OTC) medicines, as well as the marketing of such products. It operates in three distinct segments that include Human Health, Consumer Healthcare, and Animal Health. For fiscal year 2004, the company generated approximately $53 billion in revenue that contributed to over $11 billion in net income.(Pfizer, 2004)
Simple household items such as lotions, shampoos and cosmetics aren’t very expensive and are within reach for the public, yet the public is not knowledgeable of the fact that the products that they use everyday are put through a series of tests which involve the use of harmless animals. Several large commercial companies do not make products for animals; they decide that using these harmless creatures for the testing of their products, could be cause to be harmful to animals still go forward with these types of procedures on an everyday basis. Although these animals are unable to defend themselves or signs of any form of consent for the near death procedures, these companies find this as a cheap solution for testing their products before placing them on the market. There are many other alternatives to testing animals such as embryonic stem cell research. Animal experimentation is wrong and it can be avoided but companies which are greedy for money chose not to.
This allowed Pfizer to make decisions based on patterns and trends before other companies. The ability to use real-time data to drive the decision process based on market trends could be considered a competitive advantage for Pfizer.
Janssen is a division of Johnson and Johnsons that primarily focus on diseases that can help develop new strategies in improving prevention as well as developing vaccines and its accessibility to the world. The pharmaceutical company of J&J invests large amounts of money in research and development of its products. The competitive environment of Johnson and Johnson is very high for pharmaceutical companies due to which that many companies are releasing drug products and other devices. However, this company does not face any potential competitors due to which that it is a large company that provides a wide range of opportunities such as finances, and experiences. This leads to advantages compared to other competitors due to whom the pharmaceutical companies creates a barrier because of the high cost in research and development in medicine. In addition, Johnson and Johnson have to make sure that it has many suppliers for different categories for their products especially in medicine if one supplier causes shortages. Although suppliers do not bargain for the price values of its products, it still influences the price in the market in different countries. In addition, finding